Translational and clinical implications of the genetic landscape of prostate cancer

760PDNEUROENDOCRINE PROSTATE CANCER (NEPC) IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) RESISTANT TO ABIRATERONE (ABI) OR ENZALUTAMIDE (ENZ): PRELIMINARY RESULTS FROM THE SU2C/PCF/AACR WEST COAST PROSTATE CANCER DREAM TEAM (WCDT)

(2017) E.J. Small et al.   ANNALS OF ONCOLOGY

Integrative molecular profiling of routine clinical prostate cancer specimens

(2015) C. S. Grasso et al.   ANNALS OF ONCOLOGY

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

(2015) Sarit Schwartz et al.   CANCER CELL

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

(2015) D. E. Spratt et al.   CANCER RESEARCH

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

(2015) R. Ceccaldi et al.   CANCER RESEARCH

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

(2015) Y. Yamamoto et al.   CLINICAL CANCER RESEARCH

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

(2015) A. A. Azad et al.   CLINICAL CANCER RESEARCH

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

(2015) Roberta Ferraldeschi et al.   EUROPEAN UROLOGY

Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes

(2015) Scott A. Tomlins et al.   EUROPEAN UROLOGY

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment

(2015) Kunal C. Kadakia et al.   Journal of Hematology & Oncology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Spatial genomic heterogeneity within localized, multifocal prostate cancer

(2015) Paul C Boutros et al.   NATURE GENETICS

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

(2015) Colin S Cooper et al.   NATURE GENETICS

Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update

(2015) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

(2015) D. T. Miyamoto et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer

(2015) Matthew K.H. Hong et al.   Nature Communications

Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors

(2015) Daniel H. Hovelson et al.   NEOPLASIA

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report

(2015) David J. VanderWeele et al.   Frontiers in Oncology

Abstract CT239: ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)

(2015) Dana E. Rathkopf et al.   CANCER RESEARCH

Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer

(2015) Kyung Park et al.   NEOPLASIA

Castration Induces Up-Regulation of Intratumoral Androgen Biosynthesis and Androgen Receptor Expression in an Orthotopic VCaP Human Prostate Cancer Xenograft Model

(2014) Matias Knuuttila et al.   AMERICAN JOURNAL OF PATHOLOGY

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

(2014) Jonathan I. Epstein et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The MAPK pathway across different malignancies: A new perspective

(2014) Mauricio Burotto et al.   CANCER

Molecular Pathways: Targeting ETS Gene Fusions in Cancer

(2014) F. Y. Feng et al.   CLINICAL CANCER RESEARCH

Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer

(2014) Kush Dalal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer

(2014) Austin N. Kirschner et al.   JNCI-Journal of the National Cancer Institute

MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER.

(2014) Shusuke Akamatsu et al.   JOURNAL OF UROLOGY

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

(2014) Karim Fizazi et al.   LANCET ONCOLOGY

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

(2014) Emilie Lalonde et al.   LANCET ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA damage response and prostate cancer: defects, regulation and therapeutic implications

(2014) S Karanika et al.   ONCOGENE

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

(2014) Z Mounir et al.   ONCOGENE

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex

(2014) Bin He et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor clone dynamics in lethal prostate cancer

(2014) S. Carreira et al.   Science Translational Medicine

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

(2014) Colin C. Pritchard et al.   Nature Communications

Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition

(2014) Michael V. Gormally et al.   Nature Communications

The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

(2014) J. M. Lucas et al.   Cancer Discovery

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer

(2013) D Bianchini et al.   BRITISH JOURNAL OF CANCER

Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

(2013) Joachim Weischenfeldt et al.   CANCER CELL

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

(2013) H.-L. Tan et al.   CLINICAL CANCER RESEARCH

Visceral Disease in Castration-resistant Prostate Cancer

(2013) Carmel J. Pezaro et al.   EUROPEAN UROLOGY

An androgen receptor N-terminal domain antagonist for treating prostate cancer

(2013) Jae-Kyung Myung et al.   JOURNAL OF CLINICAL INVESTIGATION

Tracking the clonal origin of lethal prostate cancer

(2013) Michael C. Haffner et al.   JOURNAL OF CLINICAL INVESTIGATION

Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome

(2013) Victoria M. Raymond et al.   JOURNAL OF CLINICAL ONCOLOGY

A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells

(2013) K. S. Amin et al.   MOLECULAR CANCER THERAPEUTICS

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

The genetic epidemiology of prostate cancer and its clinical implications

(2013) Rosalind Eeles et al.   Nature Reviews Urology

Long-Term Survival of Participants in the Prostate Cancer Prevention Trial

(2013) Ian M. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

(2013) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult

(2013) J. F. Goodwin et al.   Cancer Discovery

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

(2013) S. J. Klempner et al.   Cancer Discovery

Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers

(2013) W. R. Polkinghorn et al.   Cancer Discovery

Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas

(2013) Shakuntala H. Mauzo et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Antibody-Based Detection ofERGRearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases: ERG Staining in Prostate Core Biopsies

(2012) Scott A. Tomlins et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells

(2012) B. Sahu et al.   CANCER RESEARCH

Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

(2012) D. J. Mulholland et al.   CANCER RESEARCH

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway

(2012) Hongbing Chen et al.   ENDOCRINE-RELATED CANCER

Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins

(2012) Johan Lindberg et al.   EUROPEAN UROLOGY

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer

(2012) Daniel E. Spratt et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

(2012) Cynthia X. Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

(2012) Himisha Beltran et al.   JOURNAL OF CLINICAL ONCOLOGY

A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results

(2012) Riccardo Soffietti et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

Germline Mutations inHOXB13and Prostate-Cancer Risk

(2012) Charles M. Ewing et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

(2012) S Origanti et al.   ONCOGENE

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

Alternatively spliced androgen receptor variants

(2011) Scott M Dehm et al.   ENDOCRINE-RELATED CANCER

Vitamin E and the Risk of Prostate Cancer

(2011) Eric A. Klein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity

(2011) Brent D. G. Page et al.   JOURNAL OF MEDICINAL CHEMISTRY

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Clinical implications of cancer self-seeding

(2011) Elizabeth Comen et al.   Nature Reviews Clinical Oncology

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH mutation status in prostate cancer

(2011) A F Ghiam et al.   ONCOGENE

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

(2011) A. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression

(2010) Jindan Yu et al.   CANCER CELL

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

(2010) Nallasivam Palanisamy et al.   NATURE MEDICINE

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

(2010) B Furusato et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

(2009) Deborah Bradley et al.   CANCER

Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer

(2009) I. N. Holcomb et al.   CANCER RESEARCH

Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer

(2009) Chunru Lin et al.   CELL

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

(2009) Mi Ran Kang et al.   INTERNATIONAL JOURNAL OF CANCER

Androgen Modulation of Coregulator Expression in Prostate Cancer Cells

(2009) Hannelore V. Heemers et al.   MOLECULAR ENDOCRINOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

(2009) Wennuan Liu et al.   NATURE MEDICINE

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited

(2008) E. A. Ostrander et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression

(2008) Elizabeth Vincan et al.   CLINICAL & EXPERIMENTAL METASTASIS

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

(2008) Maisa Yoshimoto et al.   MODERN PATHOLOGY